繁體中文
返回
- English
- 繁體中文
- 简体中文
- 深色
- 淺色
牛牛AI助理已提取核心訊息
On August 27, 2024, Invivyd, Inc., a biopharmaceutical company, announced positive results from its CANOPY Phase 3 clinical trial for PEMGARDA (pemivibart), a monoclonal antibody for pre-exposure prophylaxis (PrEP) of COVID-19. The trial demonstrated an 84% relative risk reduction in symptomatic COVID-19 compared to placebo in immunocompetent individuals. The data also indicated a 3% rate of confirmed symptomatic COVID-19 in immunocompromised participants, suggesting a potential signal of protection. The safety profile of pemivibart remained consistent with previous trial data, and the most common treatment-emergent adverse events were mild to moderate in severity. The U.S. FDA updated the PEMGARDA Fact Sheet for Healthcare Providers to include the 180-day exploratory clinical efficacy data. Invivyd also held a conference call to discuss the data analyses...Show More
On August 27, 2024, Invivyd, Inc., a biopharmaceutical company, announced positive results from its CANOPY Phase 3 clinical trial for PEMGARDA (pemivibart), a monoclonal antibody for pre-exposure prophylaxis (PrEP) of COVID-19. The trial demonstrated an 84% relative risk reduction in symptomatic COVID-19 compared to placebo in immunocompetent individuals. The data also indicated a 3% rate of confirmed symptomatic COVID-19 in immunocompromised participants, suggesting a potential signal of protection. The safety profile of pemivibart remained consistent with previous trial data, and the most common treatment-emergent adverse events were mild to moderate in severity. The U.S. FDA updated the PEMGARDA Fact Sheet for Healthcare Providers to include the 180-day exploratory clinical efficacy data. Invivyd also held a conference call to discuss the data analyses. The company highlighted the importance of monoclonal antibodies in providing protection against COVID-19, especially for immunocompromised individuals. Invivyd's INVYMAB platform is designed to rapidly generate new monoclonal antibodies to address evolving viral threats, and the company has received emergency use authorization (EUA) from the U.S. FDA for PEMGARDA. Full data from the CANOPY trial is expected to be published in a scientific journal.
2024年8月27日,生物製藥公司Invivyd宣佈其PEMGARDA(pemivibart)的CANOPY第3期臨床試驗取得了積極的結果,該試驗是一種用於COVID-19預先暴露預防(PrEP)的單克隆抗體。該試驗表明,對免疫競爭力正常的個體而言,與安慰劑相比,症狀性COVID-19的相對風險降低了84%。數據還顯示,對於免疫受損的參與者,確診症狀性COVID-19的發生率爲3%,這一數據可能預示着一種潛在的保護信號。pemivibart的安全性與先前的試驗數據一致,最常見的治療相關不良事件的嚴重程度爲輕度至中度。美國FDA更新了PEMGARDA醫務人員簡明資料表,包括180天的探索性臨床療...展開全部
2024年8月27日,生物製藥公司Invivyd宣佈其PEMGARDA(pemivibart)的CANOPY第3期臨床試驗取得了積極的結果,該試驗是一種用於COVID-19預先暴露預防(PrEP)的單克隆抗體。該試驗表明,對免疫競爭力正常的個體而言,與安慰劑相比,症狀性COVID-19的相對風險降低了84%。數據還顯示,對於免疫受損的參與者,確診症狀性COVID-19的發生率爲3%,這一數據可能預示着一種潛在的保護信號。pemivibart的安全性與先前的試驗數據一致,最常見的治療相關不良事件的嚴重程度爲輕度至中度。美國FDA更新了PEMGARDA醫務人員簡明資料表,包括180天的探索性臨床療效數據。Invivyd還召開了電話會議討論數據分析。該公司強調了單克隆抗體在對抗COVID-19方面的重要性,特別是對於免疫受損的個體。Invivyd的INVYMAb平台旨在快速生成新的單克隆抗體以應對不斷變化的病毒威脅,並且該公司已獲得了美國FDA關於PEMGARDA的緊急使用授權(EUA)。CANOPY試驗的完整數據預計將在科學期刊上發表。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
資訊熱榜
更新時間